|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts receivable, net of allowance of $0 and $0 as of December 31, 2023 and 2022. | ||||||||||||||||||||
| Investment at fair value - related party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Total investment at fair value - related party | ||||||||||||||||||||
| Marketable securities — related party | ||||||||||||||||||||
| Unbilled receivable | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Investment at fair value - related party | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Accounts expenses – related party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts expenses – related party | ||||||||||||||||||||
| Accounts payable — related party | ||||||||||||||||||||
| Short-term advances — related party | ||||||||||||||||||||
| Convertible note payable | ||||||||||||||||||||
| Convertible note payable — in default | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Notes Payable One | ||||||||||||||||||||
| Notes Payable Two | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Total convertible note payable — in default | ||||||||||||||||||||
| Convertible notes payable - related party, net of debt discount of $0 and $0, as of June 30, 2023 and December 31, 2022 | ||||||||||||||||||||
| Convertible note payable, net of debt discount | ||||||||||||||||||||
| Convertible note payable, net of debt discount of $0 and $0, as of March 31, 2025 and December 31, 2024 | ||||||||||||||||||||
| Notes payable — related party, in default | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total notes payable — related party, in default | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||||
| Convertible note payable, net of debt discount of $ 19,845 as of December 31, 2022 | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ Deficit | ||||||||||||||||||||
| Common stock, $0.0001 par value: 500,000,000 shares authorized; 46,852,319 and 46,852,319 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Stockholders’ Deficit | ||||||||||||||||||||
| Total Stockholders’ Deficit | ||||||||||||||||||||
| Total Liabilities and Stockholders’ Deficit | ||||||||||||||||||||
Loading...